© 2025 MJH Life Sciences™ , Patient Care Online – Primary Care News and Clinical Resources. All rights reserved.
Endocrinology
Help Shape the Future of Denosumab Treatment
As biosimilars enter the denosumab landscape, your perspective as a healthcare provider is critical in understanding what factors influence treatment decisions. This brief survey explores your views on reimbursement considerations, coding challenges, switching comfort, and drivers of biosimilar choice. As a thank you, by completing the survey, you’ll be entered into a drawing for a chance to win a $200 gift card.
Take the survey now and make your voice heard
The advisory panel laid out 4 priority actions for clinicians, policymakers, and industry.
Your daily dose of the clinical news you may have missed.
Your daily dose of the clinical news you may have missed.
Jonathan Bonnet, MD, MPH, discusses common side effects of GLP-1 medications for obesity and how nutritional and behavioral strategies can help mitigate them.
Coauthor of a recent joint advisory, Jonathan Bonnet, MD, MPH, explains how it emerged in response to the growing use of GLP-1 medications for obesity treatment.
Obesity medicine specialist Monu Khanna, MD, discusses the critical role of primary care in obesity-related risk reduction through lifestyle, behavior, and emerging therapies.
Both metformin and GLP-1 RAs have been studies for their neuroprotective effects; this study is the first head-to-head investigation and supports further research.
Individuals on GLP-1 therapy express significant concern about muscle loss, prompting lifestyle changes and highlighting the need for informed primary care guidance.
Monu Khanna, MD, offers 3 takeaways for primary care: address obesity as root cause, reduce stigma, and explore new treatments to reduce cardiovascular risk.
Type 2 diabetes and its high and rising rates in the US are the result of a perfect storm of converging systemic, behavioral, environmental, and economic factors.